Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) and Charles River Laboratories International (NYSE:CRL – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.
Profitability
This table compares Pacific Biosciences of California and Charles River Laboratories International’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pacific Biosciences of California | -82.49% | -5,752.12% | -19.52% |
| Charles River Laboratories International | -5.96% | 15.75% | 6.51% |
Analyst Recommendations
This is a summary of recent recommendations and price targets for Pacific Biosciences of California and Charles River Laboratories International, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pacific Biosciences of California | 2 | 2 | 1 | 0 | 1.80 |
| Charles River Laboratories International | 1 | 3 | 12 | 0 | 2.69 |
Risk and Volatility
Pacific Biosciences of California has a beta of 2.31, suggesting that its share price is 131% more volatile than the S&P 500. Comparatively, Charles River Laboratories International has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500.
Earnings & Valuation
This table compares Pacific Biosciences of California and Charles River Laboratories International”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pacific Biosciences of California | $160.01 million | 2.62 | -$546.38 million | ($0.43) | -3.14 |
| Charles River Laboratories International | $4.02 billion | 3.44 | -$144.34 million | ($4.85) | -59.67 |
Charles River Laboratories International has higher revenue and earnings than Pacific Biosciences of California. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
98.9% of Charles River Laboratories International shares are owned by institutional investors. 3.7% of Pacific Biosciences of California shares are owned by company insiders. Comparatively, 1.3% of Charles River Laboratories International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Charles River Laboratories International beats Pacific Biosciences of California on 9 of the 14 factors compared between the two stocks.
About Pacific Biosciences of California
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
About Charles River Laboratories International
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.
